Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin-dependent kinases 4 and 6 (CDK4/6) are serine/threonine kinases that play a central role in regulating the cell cycle, specifically the transition from G1 phase to S phase. They function as part of complexes with D-type cyclins, and their activity is essential for cell proliferation. Dysregulation of the cyclin D–CDK4/6–Rb axis is common in many cancers. Selective inhibitors targeting CDK4/6 have become important therapies for certain cancers, primarily hormone receptor-positive/HER2-negative breast cancer.
Selective inhibition of CDK4/6, leading to RB-dependent proliferative arrest and potential impacts on DNA repair mechanisms and immune modulation within tumors.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin-dependent kinases 4 and 6 (CDK4/6).